Navigation Links
Medivation Announces Participation in Upcoming Conferences
Date:9/9/2009

SAN FRANCISCO, Sept. 9 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:

  • The BioCentury NewsMakers in the Biotech Industry Conference on Wednesday, September 16, at 11:30 a.m. Eastern Time at the Millennium Broadway Hotel in New York
  • The UBS Global Life Sciences Conference on Wednesday, September 23, at 9:00 a.m. Eastern Time at the Grand Hyatt in New York

Dr. Hung will provide an overview of Medivation and its clinical development programs including dimebon (latrepirdine) for Alzheimer's and Huntington diseases and MDV3100 for prostate cancer.

A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, the Company is conducting a broad dimebon clinical development program that i
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease
2. Medivation Announces Pricing of Public Offering
3. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
4. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
5. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
6. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
7. Medivation Presents New Data on Dimebons Novel Mechanism of Action
8. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
9. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
10. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
11. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Dr. Greg Leyer of ... annual Scripps Natural Supplements Pre-Conference seminar on probiotics in San ... an annual continuing education conference for health care professionals. This ... the topic of probiotics in health. Dr. Leyer spoke about ...
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... GMO corn cases filed across the United States, and ... being consolidated in a Kansas federal court for pretrial proceedings. ... Corn Litigation, MDL No. 2591 in the U.S. District Court ... GMO corn multidistrict litigation (MDL) has been handed over to ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Professionals, LLC.,today announced the addition of Mark Scherling ... join FCP as Program,Management Office and Siemens Practice ... IT thought leadership,experience to FCP. Prior to joining ... support at Catholic Healthcare West. Prior to that,responsibility, ...
... a,Cambridge UK based spinal implant development company, has ... and existing investors to further,develop and commercialise its ... by Alliance Trust Equity Partners (ATEP) and First,Ventures ... of CAdisc L, the,lumbar version of Ranier,s compliant ...
... Germany, February 18 JADO Technologies GmbH,the leading ... from a Phase IIa clinical trial of its ... dermatitis. TF002, a topical,formulation of miltefosine, exerts its ... in the lipid membrane of cells that,play a ...
Cached Biology Technology:FCP Welcomes Mark Scherling 2Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs 2Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs 3JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis 2JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis 3
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... technology and tech stocks, releases video from the CES 2015 ... security consultant Apollo Robbins . Apollo shows ... Wocket™ biometric smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  Since its launch in ... of people to eliminate the pain of trying to remember ... their own biometrics fused to their smartphones. To assist people ... Labs , the company that created 1U and focuses on ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... University of Iowa Roy J. and Lucille A. ... toward a potential treatment for Huntington's disease (HD). ... scientists reduced levels of the disease-causing HD protein ... neurological abnormalities normally associated with the disease.HD is ...
... A research team from Purdue University and the University ... atmosphere may be more effective at cleansing itself of ... , Scientists, including Joseph S. Francisco, have learned that ... effectively than previously thought to produce substances that "scrub" ...
... headed by Professor Hans-Georg Kräusslich at Heidelberg University ... Applied Tumor Virology of the Deutsches Krebsforschungszentrum (German ... to label Human Immunodeficiency Viruses (HIV) for visual ... virus. , The labeling permits scientists to observe ...
Cached Biology News:U. Iowa researchers improve Huntington's disease symptoms in mice 2U. Iowa researchers improve Huntington's disease symptoms in mice 3Atmosphere may cleanse itself better than previously thought 2Atmosphere may cleanse itself better than previously thought 3Atmosphere may cleanse itself better than previously thought 4Virologists make major step towards understanding the process of HIV infection 2
... Supply, 1. 3500 V, 400 mA, 200 ... and linear voltage ramp modes.Linear voltage ramp ... IPG strips quickly without danger of overheating.Volt-hour ... gel thickness, sample ionic strength, and temperature.Stores ...
Human Aminopeptidase P1/XPNPEP1 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
Template and primers for preparation of internal control spots...
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
Biology Products: